Skip to main content
DFTX
NASDAQ Life Sciences

Definium Reports $77.1M Q1 Net Loss, Driven by Increased R&D for Phase 3 Trials

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$22.587
Mkt Cap
$2.53B
52W Low
$6.03
52W High
$26.25
52W Position info
275% above low
Off High info
14% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

DFTX has more than doubled off its 52-week low of $6.03.

Summary

Definium Therapeutics reported a Q1 net loss of $77.1 million, or $0.71 per share, which widened compared to the prior year. This increased loss was primarily due to higher R&D costs associated with advancing its DT120 ODT clinical trials, including completing enrollment in key Phase 3 studies. The company reaffirmed its cash and investments of $373.4 million are sufficient to fund operations into 2028, consistent with the capital raise reported in its last 10-K. While the widening net loss is a negative financial outcome, the underlying cause—increased investment in late-stage clinical trials—is a strategic move for a biopharma company. The reaffirmed cash runway provides stability, mitigating immediate concerns about liquidity despite the current unprofitability. Investors will be watching for topline data from three Phase 3 DT120 ODT studies expected by the end of Q3 2026, and the planned initiation of a Phase 3 PTSD study in 2027.

At the time of this announcement, DFTX was trading at $22.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $6.03 to $26.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

DFTX - Latest Insights

DFTX
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $29.09 info
Change: -$6.91 (-19%) info
Market Cap: $3.991B info
DFTX
Nov 09, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $35.36
Real-time Price: $29.09 info
Change: -$6.26 (-18%) info
Market Cap: $3.991B info
DFTX
Sep 14, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $45.00
Real-time Price: $29.09 info
Change: -$15.91 (-35%) info
Market Cap: $3.991B info
DFTX
Sep 14, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $41.46
Real-time Price: $29.09 info
Change: -$12.37 (-30%) info
Market Cap: $3.991B info
DFTX
Sep 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.39
Real-time Price: $29.09 info
Change: -$10.30 (-26%) info
Market Cap: $3.991B info